Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 5, 2015, Pages 2596-2606

  Seki, Takahiro ^a   Suyama Kagitani, Akemi ^a   Kawauchi Miki, Shinobu ^a   Miki, Shigeru ^a   Wakasa Morimoto, Chiaki ^a   Akihisa, Erika ^a   Nakahara, Koichiro ^a   Kobayashi, Masanori ^a   Underwood, Mark R ^b   Sato, Akihiko ^a   Fujiwara, Tamio ^a   Yoshinaga, Tomokazu ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; RALTEGRAVIR; FUSED HETEROCYCLIC RINGS; INTEGRASE; INTEGRASE INHIBITOR; P31 INTEGRASE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; QUINOLONE DERIVATIVE;

ANTIVIRAL RESISTANCE; ARTICLE; DRUG EFFECT; DRUG ELIMINATION; EC50; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; INVESTIGATIVE PROCEDURES; PRIORITY JOURNAL; VIRUS INFECTIVITY; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION; WILD TYPE; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION;

DRUG RESISTANCE, VIRAL; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; MUTATION; QUINOLONES; RALTEGRAVIR POTASSIUM;

EID: 84931292120     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04844-14     Document Type: Article

References (37)

1. UNAIDS. 2013. Joint United Nations Programme on HIV/AIDS (UNAIDS) report on the global AIDS epidemic 2013. UNAIDS, Geneva, Switzerland. http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf.
2. Fernández-Montero JV, Vispo E, Soriano V. 2014. Emerging antiretroviral drugs. Expert Opin Pharmacother 15:211-219. http://dx.doi.org/10.1517/14656566.2014.863277.
3. DeJesus E, Berger D, Markowitz M, Cohen C, Hawkins T, Ruane P, Elion R, Farthing C, Zhong L, Cheng AK, McColl D, Kearney BP, 183-0101 Study Team. 2006. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 43:1-5. http://dx.doi.org/10.1097/01.qai.0000233308.82860.2f.
4. DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP, GS-236-0103 Study Team. 2012. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 379:2429-2438. http://dx.doi.org/10.1016/S0140-6736(12)60918-0.
5. Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, Wenning L, Zhao J, Teppler H. 2006. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 43:509-515. http://dx.doi.org/10.1097/QAI.0b013e31802b4956.
6. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H, Protocol 004 Part II Study Team. 2007. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 46:125-133. http://dx.doi.org/10.1097/QAI.0b013e318157131c.
7. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. 2011. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 203:1204-1214. http://dx.doi.org/10.1093/infdis/jir025.
8. Garrido C, Villacian J, Zahonero N, Pattery T, Garcia F, Gutierrez F, Caballero E, Van Houtte M, Soriano V, de Mendoza C, SINRES Group. 2012. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother 56:2873-2878. http://dx.doi.org/10.1128/AAC.06170-11.
9. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade- Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S, Extended SAILING Study Team. 2013. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 382:700-708. http://dx.doi.org/10.1016/S0140-6736(13)61221-0.
10. Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, Molina JM, Chas J, Durant J, Moreno S, Doroana M, Ait-Khaled M, Huang J, Min S, Song I, Vavro C, Nichols G, Yeo JM, VIKING-3 Study Group. 2014. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 210:354-362. http://dx.doi.org/10.1093/infdis/jiu051.
11. Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S, ING114915 Study Team. 2014. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 383:2222-2231. http://dx.doi.org/10.1016/S0140-6736(14)60084-2.
12. Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S, Extended SPRING-2 Study Group. 2013. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 13:927-935. http://dx.doi.org/10.1016/S1473-3099(13)70257-3.
13. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G, SINGLE Investigators. 2013. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 369:1807-1818. http://dx.doi.org/10.1056/NEJMoa1215541.
14. Arribas JR, Eron J. 2013. Advances in antiretroviral therapy. Curr Opin HIV AIDS 8:341-349. http://dx.doi.org/10.1097/COH.0b013e328361fabd.
15. U.S. Department of Health & Human Services. 2013. Recommendation on integrase inhibitor use in antiretroviral treatment-naive HIV-infected individuals from the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. AIDSinfo, U.S. Department of Health and Human Services, Rockville, MD. http://aidsinfo.nih.gov/contentfiles/AdultARV-INSTIRecommendations.pdf.
16. Geretti AM, Armenia D, Ceccherini-Silberstein F. 2012. Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Curr Opin Infect Dis 25:677-686. http://dx.doi.org/10.1097/QCO.0b013e32835a1de7.
17. Wensing AM, Calvez V, Gunthard HF, Johnson VA, Paredes R, Pillay D, Shafer RW, Richman DD. 2014. 2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med 22:642-650.
18. Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, Poizot-Martin I, Richmond G, Soriano V, Ait-Khaled M, Fujiwara T, Huang J, Min S, Vavro C, Yeo J, VIKING Study Group. 2013. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 207:740-748. http://dx.doi.org/10.1093/infdis/jis750.
19. th Conf Retrovir Oppor Infect, 27 February to 2 March 2011, Boston, MA.
20. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T. 2011. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 55:813-821. http://dx.doi.org/10.1128/AAC.01209-10.
21. Isaka Y, Sato A, Miki S, Kawauchi S, Sakaida H, Hori T, Uchiyama T, Adachi A, Hayami M, Fujiwara T, Yoshie O. 1999. Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5. Virology 264:237-243. http://dx.doi.org/10.1006/viro.1999.0006.
22. Harada S, Koyanagi Y, Yamamoto N. 1985. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 229:563-566. http://dx.doi.org/10.1126/science.2992081.
23. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59:284-291.
24. Garvey EP, Johns BA, Gartland MJ, Foster SA, Miller WH, Ferris RG, Hazen RJ, Underwood MR, Boros EE, Thompson JB, Weatherhead JG, Koble CS, Allen SH, Schaller LT, Sherrill RG, Yoshinaga T, Kobayashi M, Wakasa-Morimoto C, Miki S, Nakahara K, Noshi T, Sato A, Fujiwara T. 2008. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother 52:901-908. http://dx.doi.org/10.1128/AAC.01218-07.
25. Nakahara K, Wakasa-Morimoto C, Kobayashi M, Miki S, Noshi T, Seki T, Kanamori-Koyama M, Kawauchi S, Suyama A, Fujishita T, Yoshinaga T, Garvey EP, Johns BA, Foster SA, Underwood MR, Sato A, Fujiwara T. 2009. Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antiviral Res 81:141-146. http://dx.doi.org/10.1016/j.antiviral.2008.10.007.
26. Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, Niedziela-Majka A, Barnes TL, Novikov N, Chen X, Svarovskaia ES, McColl DJ, White KL, Miller MD. 2013. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother 57:2654-2663. http://dx.doi.org/10.1128/AAC.02568-12.
27. McColl DJ, Chen X. 2010. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res 85:101-118. http://dx.doi.org/10.1016/j.antiviral.2009.11.004.
28. Vavro C, Hasan S, Madsen H, Horton J, DeAnda F, Martin-Carpenter L, Sato A, Cuffe R, Chen S, Underwood M, Nichols G. 2013. Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572). Antimicrob Agents Chemother 57:1379-1384. http://dx.doi.org/10.1128/AAC.01791-12.
29. Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA. 2012. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 86:2696-2705. http://dx.doi.org/10.1128/JVI.06591-11.
30. Quashie PK, Mesplede T, Han YS, Veres T, Osman N, Hassounah S, Sloan RD, Xu HT, Wainberg MA. 2013. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob Agents Chemother 57:6223-6235. http://dx.doi.org/10.1128/AAC.01835-13.
31. Johns BA, Kawasuji T, Weatherhead JG, Taishi T, Temelkoff DP, Yoshida H, Akiyama T, Taoda Y, Murai H, Kiyama R, Fuji M, Tanimoto N, Jeffrey J, Foster SA, Yoshinaga T, Seki T, Kobayashi M, Sato A, Johnson MN, Garvey EP, Fujiwara T. 2013. Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744). J Med Chem 56:5901-5916. http://dx.doi.org/10.1021/jm400645w.
32. Kawasuji T, Fuji M, Yoshinaga T, Sato A, Fujiwara T, Kiyama R. 2006. A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors. Bioorg Med Chem 14:8420-8429. http://dx.doi.org/10.1016/j.bmc.2006.08.043.
33. Kawasuji T, Johns BA, Yoshida H, Taishi T, Taoda Y, Murai H, Kiyama R, Fuji M, Yoshinaga T, Seki T, Kobayashi M, Sato A, Fujiwara T. 2012. Carbamoyl pyridone HIV-1 integrase inhibitors. 1. Molecular design and establishment of an advanced two-metal binding pharmacophore. J Med Chem 55:8735-8744. http://dx.doi.org/10.1021/jm3010459.
34. Kawasuji T, Johns BA, Yoshida H, Weatherhead JG, Akiyama T, Taishi T, Taoda Y, Mikamiyama-Iwata M, Murai H, Kiyama R, Fuji M, Tanimoto N, Yoshinaga T, Seki T, Kobayashi M, Sato A, Garvey EP, Fujiwara T. 2013. Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles. J Med Chem 56:1124-1135. http://dx.doi.org/10.1021/jm301550c.
35. Kawasuji T, Yoshinaga T, Sato A, Yodo M, Fujiwara T, Kiyama R. 2006. A platform for designing HIV integrase inhibitors. Part 1: 2-hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores. Bioorg Med Chem 14:8430-8445. http://dx.doi.org/10.1016/j.bmc.2006.08.044.
36. Deanda F, Hightower KE, Nolte RT, Hattori K, Yoshinaga T, Kawasuji T, Underwood MR. 2013. Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics. PLoS One 8:e77448. http://dx.doi.org/10.1371/journal.pone.0077448.
37. Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, Tomberlin GH, Carter HL, III, Broderick T, Sigethy S, Seki T, Kobayashi M, Underwood MR. 2011. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 55:4552-4559. http://dx.doi.org/10.1128/AAC.00157-11.